Jansitin Duo

Metformin Hydrochloride and Sitagliptin, the active ingredient in Jansitin Duo, is a Biguanide / DPP‑4 inhibitor presented as a fixed‑dose oral tablet for oral use. It treats type 2 diabetes mellitus in adults by improving glycaemic control. GNH USA supplies Jansitin Duo as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jansitin Duo combines metformin and sitagliptin to manage hyperglycaemia in type 2 diabetes mellitus.

- Type 2 diabetes mellitus: improves glycaemic control in adults when added to diet and exercise. - Inadequate control on metformin alone: provides additional DPP‑4 inhibition to lower blood glucose. - Combination therapy requirement: simplifies regimen by delivering two agents in a single tablet.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Hypoglycaemia: especially when used with insulin or sulfonylureas. - Upper respiratory tract infection: mild symptoms. - Dizziness: transient episodes.

Serious or Rare Side Effects: - Lactic acidosis: rare but life‑threatening metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Renal impairment: worsening kidney function. - Severe hypoglycaemia: prolonged low blood glucose requiring assistance.

Before initiating Jansitin Duo, assess patient-specific factors and monitor regularly. - Renal function: evaluate creatinine clearance and adjust therapy as needed. - Hepatic function: use with caution in patients with liver disease. - Risk of lactic acidosis: avoid in severe renal impairment or conditions predisposing to hypoxia. - Pregnancy and lactation: weigh benefits against potential risks; consult a specialist. - Drug interactions: review concomitant medications for possible interactions. - Store at ambient temperature: keep in original container, protect from moisture and heat.

Jansitin Duo may interact with several medicines; monitoring is essential.

Major Interactions (Avoid): - Intravenous iodinated contrast agents: may precipitate metformin‑associated lactic acidosis. - Strong CYP3A4 inhibitors (e.g., ketoconazole): increase sitagliptin exposure. - Alcohol abuse: heightens risk of lactic acidosis. - Renal replacement therapy: metformin accumulation risk. - Sulfonylureas or insulin: potentiate hypoglycaemia.

Moderate Interactions (Monitor Closely): - Diuretics: may affect renal clearance of metformin. - Corticosteroids: can raise blood glucose, requiring dose adjustment. - Beta‑blockers: may mask hypoglycaemia symptoms. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Anticoagulants (e.g., warfarin): metformin may alter INR, requiring periodic checks.